Prostin E2 Vaginal Tablets - Summary of Product Characteristics (SMPC) - Print Friendly - (Emc)
Prostin E2 Vaginal Tablets - Summary of Product Characteristics (SMPC) - Print Friendly - (Emc)
Prostin E2 Vaginal Tablets - Summary of Product Characteristics (SMPC) - Print Friendly - (Emc)
Oxytocic agent. Prostin E2 Vaginal Tablets are indicated for the induction of labour, especially in patients with favourable
induction features, when there are no foetal or maternal contra-indications.
Usage is restricted to qualified health care professionals and to hospitals and clinics with specialised obstetric units with facilities
for continuous monitoring.
The recommended dose should not be exceeded, and the dosing interval should not be shortened as this increases the risk of
uterine hyperstimulation, uterine rupture, uterine haemorrhage, foetal and neonatal death.
Posology
Adults
One tablet to be inserted high into the posterior fornix. A second tablet may be inserted after six to eight hours if labour is not
established. Maximum dose 6 mg.
Elderly
Not applicable.
Paediatric population
Not applicable.
Method of administration
Vaginally. The tablets should be inserted high into the posterior fornix.
4.3 Contraindications
Hypersensitivity to the active substance(s) or to any of the excipients listed in section 6.1.
Prostin E2 Vaginal Tablets should not be used where the patient is sensitive to prostaglandins or other constituents of the tablet.
Prostin E2 Vaginal Tablets are not recommended in the following circumstances:
• For patients in whom oxytocic drugs are generally contra-indicated or where prolonged contractions of the uterus are
considered inappropriate such as:
- Cases with a history of Caesarean section or major uterine surgery.
- Cases where there is cephalopelvic disproportion.
- Cases in which foetal malpresentation is present.
- Cases where there is clinical suspicion or definite evidence of pre-existing foetal distress.
- Cases in which there is a history of difficult labour and/or traumatic delivery.
• In patients with a past history of, or existing, pelvic inflammatory disease, unless adequate prior treatment has been instituted.
https://www.medicines.org.uk/emc/product/1091/smpc/print 1/5
2/18/24, 1:20 PM Prostin E2 Vaginal Tablets - Summary of Product Characteristics (SmPC) - print friendly - (emc)
• In patients where there is clinical suspicion or definite evidence of placenta praevia or unexplained vaginal bleeding during this
pregnancy.
• Patients with active cardiac, pulmonary, renal or hepatic disease.
This product is only available to hospitals and clinics with specialised obstetric units and should only be used
where 24-hour resident medical cover is provided.
Use caution in handling this product to prevent contact with skin. Wash hands thoroughly with soap and water after
administration.
As with any oxytocic agent, the risk of uterine rupture should be considered. Concomitant medication, maternal and foetal status
should be taken into consideration in order to minimise the risk of uterine hyperstimulation, uterine rupture, uterine haemorrhage,
foetal and neonatal death. Careful and regular monitoring of uterine activity and foetal heart rate should be conducted during use
of dinoprostone. Patients who develop uterine hypertonus or hypercontractility, or in whom unusual foetal heart rate patterns
develop, should be managed in a manner that addresses the welfare of the foetus and mother.
Caution should be exercised in the administration of Prostin E2 Vaginal Tablets for the induction of labour in patients with:
• asthma or a history of asthma
• epilepsy or a history of epilepsy
• glaucoma or raised intra-ocular pressure
• compromised cardiovascular, hepatic, or renal function
• hypertension
• ruptured chorioamniotic membranes.
Dinoprostone should be used with caution in patients with multiple pregnancy.
In labour induction, cephalopelvic relationships should be carefully evaluated before use of Prostin E2 Vaginal Tablets. During
use, uterine activity, foetal status and the progression of cervical dilation should be carefully monitored to detect possible
evidence of undesired responses, e.g. hypertonus, sustained uterine contractions, or foetal distress.
In cases where there is a known history of hypertonic uterine contractility or tetanic uterine contractions, it is recommended that
uterine activity and the state of the foetus (where applicable) should be continuously monitored throughout labour. The possibility
of uterine rupture should be borne in mind where high-tone uterine contractions are sustained.
Women aged 35 years or older, those with complications during pregnancy and those with a gestational age over 40 weeks have
been shown to have an increased risk of post-partum disseminated intravascular coagulation. In addition, these factors may
further increase the risk associated with labour induction (see section 4.8). Therefore, in these women, use of dinoprostone
should be undertaken with caution. Measures should be applied to detect as soon as possible an evolving fibrinolysis in the
immediate post-partum phase.
4.5 Interaction with other medicinal products and other forms of interaction
The response to oxytocin may be accentuated in the presence of exogenous prostaglandin therapy. Concurrent use with other
oxytocic agents is not recommended. A dosing interval of at least 6 hours is recommended in case of oxytocin use is considered
necessary following dinoprostone administration. If used in sequence, the patient's uterine activity should be carefully monitored.
Pregnancy
Prostin E2 Vaginal Tablets are only used during pregnancy, to induce labour.
Breast-feeding
Prostaglandins are excreted in breast milk. This is not expected to be a hazard given the circumstances in which the product is
used.
Not relevant.
https://www.medicines.org.uk/emc/product/1091/smpc/print 2/5
2/18/24, 1:20 PM Prostin E2 Vaginal Tablets - Summary of Product Characteristics (SmPC) - print friendly - (emc)
4.8 Undesirable effects
4.9 Overdose
Overdosage may be expressed by uterine hypercontractility and uterine hypertonus. During use, uterine activity, foetal status
and the progression of cervical dilation should be carefully monitored to detect possible evidence of undesired responses, e.g.
hypertonus, sustained uterine contractions, or foetal distress. Because of the transient nature of prostaglandin E2 (PGE2)-
induced myometrial hyperstimulation, non-specific, conservative management was found to be effective in the vast majority of
cases: i.e. maternal position change and administration of oxygen to the mother. If conservative management is not effective, ß-
adrenergic drugs may be used as a treatment of hyperstimulation following administration of PGE2 for cervical ripening, in
appropriate patients.
5. Pharmacological properties
5.1 Pharmacodynamic properties
Following insertion of the tablet, PGE2 absorption (as measured by the presence of PGE2 metabolites) increases to reach a
peak at about 40 minutes. PGE2 is rapidly metabolised to 13, 14-dihydro, 15-keto PGE2 which is converted to 13, 14-dihydro,
https://www.medicines.org.uk/emc/product/1091/smpc/print 3/5
2/18/24, 1:20 PM Prostin E2 Vaginal Tablets - Summary of Product Characteristics (SmPC) - print friendly - (emc)
15-keto PGA2 which binds covalently to albumen.
There has been found to be inter-patient variability regarding systemic absorption of PGE2. This can be attributed to different
conditions of the vaginal mucosa between patients.
Animal studies lasting several weeks at high doses have shown that prostaglandins of the E and F series can induce proliferation
of bone. Such effects have also been noted in newborn infants who received prostaglandin E1 during prolonged treatment. There
is no evidence that short-term administration of prostaglandin E2 can cause similar bone effects.
6. Pharmaceutical particulars
6.1 List of excipients
Lactose
Microcrystalline Cellulose
Colloidal Silicon Dioxide
Maize Starch
Magnesium Stearate.
6.2 Incompatibilities
Not applicable.
2 years.
Amber glass bottle with screw cap and tac seal. Each bottle contains a desiccant capsule and 4 tablets.
Aluminium foil strip of 4 tablets, each box containing 4 or 8 tablets.
Not all pack sizes may be marketed.
https://www.medicines.org.uk/emc/product/1091/smpc/print 4/5
2/18/24, 1:20 PM Prostin E2 Vaginal Tablets - Summary of Product Characteristics (SmPC) - print friendly - (emc)
https://www.medicines.org.uk/emc/product/1091/smpc/print 5/5